Connection
Thomas Flaig to Vascular Endothelial Growth Factor A
This is a "connection" page, showing publications Thomas Flaig has written about Vascular Endothelial Growth Factor A.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.335 |
|
|
|
-
Yang X, Flaig TW. Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. Int Braz J Urol. 2010 May-Jun; 36(3):273-82.
Score: 0.300
-
Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist. 2019 09; 24(9):1149-e807.
Score: 0.035